Click to Download
PRESS RELEASE
11 March 2025
Press Release
Media Contacts:
IB Communications
CellProthera Presenting at Advanced Therapies Congress 2025 in London
Ibon Garitaonandia, CellProthera's CSO, will present on “Development of cell-based therapies for Post-acute Myocardial Infarction.”
Mulhouse, France, March 11, 2025 – CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, announced it will be presenting next week at Terrapinn’s Advanced Therapies Congress 2025, held in London. Ibon Garitaonandia, PhD, MBA, Chief Scientific Officer, will present on “Development of cell-based therapies for Post-acute Myocardial Infarction” on Wednesday, March 19 at 3:20 p.m., as part of the conference’s Cell Therapy track. Dr. Garitaonandia will also take part in the opening panel discussion for the Gene Modified Cell Therapy track on autologous vs allogeneic approaches on Tuesday, March 18 at 11 a.m.
Following a positive pre-IND meeting with the U.S. Food and Drug Administration last year, CellProthera remains on track for a U.S. and international Phase III trial for ProtheraCytes® in patients following a severe heart attack for ProtheraCytes®, an autologous CD34+ stem cell therapy that demonstrated positive results in a Phase II trial that concluded last year.
At the conference, Dr. Garitaonandia’s presentation will include a discussion of the cornerstones of the development program, the Phase II results, and a look at the design and outlook for its forthcoming Phase III trial.
For the full Advanced Therapies Congress 2025 schedule, visit www.terrapinn.com/congress/advanced-therapies/agenda.stm
About CellProthera
CellProthera is a regenerative cell therapy developer specializing in cardiovascular diseases with a leading program in myocardial infarction. CellProthera has developed a unique GMP-compliant cell expansion process as well as a proprietary automation technology for in vitro production of a large quantity of purified, CD34+ stem cells. Its lead therapy ProtheraCytes®, is an autologous cell therapy developed for body regeneration and targeted to regenerate various damaged tissues, including cardiac tissue. ProtheraCytes is registered as an Advanced Therapy Medicinal Product – ATMP – by the European Medicines Agency (EMA). CellProthera’s proprietary technology platform comprises an automated expansion device called StemXpand® and its single use kit StemPack®. CellProthera is headquartered in France.